Doximity Inc (DOCS)

Investment Committee Summary

Investment Thesis

Doximity operates a digital platform for medical professionals — a network business rather than a manufacturer, which is why it earns an operating margin near 30% (reported GAAP, TTM to Jun 2026) on modest capital intensity and holds net cash of ~$0.7B. At $30.50 on 10 October 2026 the shares are trading rich to the triangulated $23.38 (-23%), the probability-weighted target is $20.90, and the forward multiple sits near 23x. Two things should be said plainly. First, the engine routes the name through a life-science tools and services driver set — pharmaceutical customers' budgets and clinical funding — which captures roughly the right macro exposure but the wrong business model, so the archetype fit is loose. Second, the shares now sit far closer to the bottom of their 52-week range than the top, so a violent de-rating has already happened rather than being ahead. What decides the outcome is whether monetisation per active professional keeps rising when the customers funding it cut promotional budgets, because at this margin the operating leverage runs hard in both directions. The most damaging risk is a funding and spending reset among those customers, since there is no variable cost base to cut in response.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($30.50) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The bear mechanism is budget dependency. A platform earning an operating margin near 30% (reported GAAP, TTM to Jun 2026) does so because serving one more professional costs close to nothing; the corollary is that its revenue is somebody else's discretionary spend. When development funding tightens or a launch calendar thins, promotional budgets are among the first lines cut, and the margin has no variable cost to shed in defence. A forward multiple near 23x on falling revenue then de-rates twice — earnings down, rating down — and the extraordinary width of the 52-week range is evidence that this market will reprice the name by a multiple of its value within a single year. The structural path lands below the 52-week low. One caution about the engine itself: its probability of the shares clearing today's price sits well under its own plausibility band, which points to a downside weighting more severe than the evidence supports.

Key Debate

P/E Multiple explains 91% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 22.6× consensus forward EPS, vs the house DCF terminal 14.0×, and a peer median 17.0×. The house DCF sits 12% below spot, so the market is pricing in more than the house case — roughly 2.0pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($9.52) to a 'Bull — Re-Rate' bull case ($38.28); the probability-weighted blend (PWEV $20.90) is -31% versus spot.

SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (3.5% of shares, on SBC ≈ 19% of revenue), trimming the gross PWEV of $21.63 to $20.90 (-3.4%). SBC is charged once, as dilution — never also deducted from FCF.

Scenario rationale — the driver path behind every target:

• Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $9.52). Structural impairment — biopharma-funding / China / demand reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• R&D-Spend Recession (17%, $16.16). Cyclical downturn — biopharma R&D & commercial budgets + consumable/service pull-through weakens for 1–2 years before normalising.
• Base — Tools + Services Growth (35%, $22.45). Mid-cycle — normalised biopharma R&D & commercial budgets + consumable/service pull-through; disciplined capital allocation; steady returns.
• Growth — Bioprocessing / Biologics Recovery (20%, $30.31). Upside — biopharma spend recovery + mix lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $38.28). Upside tail — sustained tight conditions or a structural re-rate on biopharma spend recovery + mix.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $19.65 and 7% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (91% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — explicit-period cash flows with an exit-multiple terminal

A 5-year cash-flow path discounted at a WACC of 8.5%, plus a terminal value of final-year FCF × 14.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $26.75. The terminal value is 72% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (47%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $11.99; the peer-median forward P/E is 17.0x, but the engine carries no P/E-implied price for this name (fewer than three same-sub-industry peers carry a forward multiple). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 71% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)

Tornado — DCF/share swing by driver (widest first)

Company lever — value at the base multiple vs Life-Science Tools, Services & Software multiple (base 15.0x)

Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.

Peer Quality & Weighting

Quality-weighted forward P/E: 17.7× (simple median 17.0×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $17.15–$72.24, centre $35.20 (+15% vs spot); spot sits at the 24th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Biopharma-Funding / China / Bioprocessing Reset' target ÷ price). 'Structural — Biopharma-Funding / China / Bioprocessing Reset' ($9.52, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $38.28.

Company Overview & Business Model

Doximity Inc — HEALTHCARE · HEALTH INFORMATION SERVICES. Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians.

Company description as supplied by Alpha Vantage; not checked against the company's filings.

How it makes money.

† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.

Reported operating margin (GAAP): 33.3% for the fiscal year ended 2026-03-31; 29.7% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Edge. Wide moat — inferred from a 30% (reported GAAP, TTM to Jun 2026) operating margin and the Life-Science tools, services & software business model. Durable pricing power supports a terminal multiple above the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

For comparison, the company's reported GAAP operating margin was 33.3% for the fiscal year ended 2026-03-31; 29.7% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Devices Tools

This name sits in the Health Care — Devices Tools cluster as a Life-Science tools, services & software name. biopharma R&D & commercial budgets + consumable/service pull-through. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: ILMN (Life-Science tools, services & software) · MEDP (Life-Science tools, services & software) · PEN (medical devices & equipment) · GMED (medical devices & equipment) · BRKR (medical devices & equipment) · BIO (Life-Science tools, services & software) · AVTR (Life-Science tools, services & software) · LNTH (medical devices & equipment) · LIVN (medical devices & equipment) · NVST (medical devices & equipment) · DOCS (Life-Science tools, services & software) · HAE (medical devices & equipment) · XRAY (medical devices & equipment)

Mapping note: name-level 'Structural — Biopharma-Funding / China / Bioprocessing Reset' (20%) + 'R&D-Spend Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — Bioprocessing / Biologics Recovery' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Devices Tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2026-03-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 19% of revenue; cash conversion (OCF/NI) 166% — cash-backed.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q3): management +0.41 vs analyst floor +0.16 → delta +0.26 (n=20 mgmt / 14 Q&A; 18th pctile across the S&P book, z -1.0).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 119 articles): avg ticker sentiment -0.06 (bullish 8% / bearish 23%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-11-05 (~27d) — Quarterly earnings — est. EPS $0.19 (AV EARNINGS_CALENDAR)

Forecast Track Record

• EPS surprise: beat 75% of the last 8 quarters; average surprise +15.2%.

Catalyst Timeline

5 catalysts in the next 90 days (of 12 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 1 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 0.65 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 30.5 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $30.50; 52-week range $17.15–$72.24; engine rating SELL; house target $20.90 (-31%). (source: Alpha Vantage 2026-10-09, 10 October 2026)
• INFERENCE: Triangulated FV $23.38 (-23% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

72.4/100 (confidence band 60.5–84.4), 97th percentile of 893 covered names (as of 2026-10-09). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 72.1 → 71.9 → 73.4 → 73.6 → 73.4 → 73.4 → 73.4 → 73.0.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $21.63.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Portfolio Interaction (Focus Book)

This name is in the top-conviction focus book. Equal-weight book vol 8.1%; diversification benefit 78.7% vs the gross-weighted average single-name vol — combining correlation, the short leg hedging the long leg, and net exposure below 1.0; not diversification alone.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -31% vs spot
• Monte Carlo median implies -36% vs spot
• DCF fair value (exit-multiple terminal) implies -12% vs spot
• Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -69% vs spot
• Net: the valuation anchor itself sits 23.3% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $1B + PV(terminal) $3B = EV $4B; + net cash $0.7B → equity $5B ÷ diluted shares $0.18B = $26.75/share (exit-multiple terminal).

• Gordon terminal → $30.35/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
• Incremental ROIC on the forecast capex ≈ 36% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $11.99 (no P/E-implied price — fewer than three same-sub-industry peers carry a forward multiple).

Weighted fair-value math

Model Calibration Caveats

Raised by the model's own checks on its run of 10 October 2026 (prices as of 2026-10-09). They concern how the model was calibrated, not the company; read the figures they touch with them in mind.

• The Monte Carlo gives only a 7% probability of the price finishing above today's; the house treats readings under 30% as a sign the downside assumptions may be too severe.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Terminal × ±15% (5.0); Revenue CAGR ±3pp (5.0); Model op margin ±3pp (3.0); WACC ±1pp (2.0); Capex intensity ±15% (1.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 14×, FY+5 revenue $1B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.